目的 探討平消膠囊聯(lián)合米非司酮治療子宮肌瘤的臨床效果。方法 選取2015年6月—2017年6月衡水市第二人民醫(yī)院收治的134例子宮肌瘤患者，隨機(jī)分為對照組和治療組，每組各67例。對照組口服米非司酮片，自月經(jīng)來潮第2天開始，25 mg/次，1次/d。治療組在對照組治療基礎(chǔ)上口服平消膠囊，1.38 g/次，3次/d。兩組均連續(xù)治療3個月。觀察兩組的臨床療效，同時比較兩組治療前后卵泡生成激素（FSH）、孕酮（P）、雌二醇（E₂）、子宮肌瘤體積、白細(xì)胞介素（IL）-6、CD³⁺ T細(xì)胞百分率、CD⁴⁺/CD⁸⁺比值、孕激素受體（PR）、表皮生長因子受體（EGFR）表達(dá)強(qiáng)度。結(jié)果 治療后，對照組和治療組患者的總有效率分別為80.6%、91.0%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，血清FSH、E₂、P水平、肌瘤體積、IL-6、PR和EGFR表達(dá)強(qiáng)度均較治療前顯著降低，外周血CD³⁺、CD⁴⁺/CD⁸⁺值均明顯增加，同組治療前后比較差異均具有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組FSH、E₂、P水平、肌瘤體積、IL-6、PR和EGFR表達(dá)強(qiáng)度均顯著低于對照組，外周血CD³⁺、CD⁴⁺/CD⁸⁺值高于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 平消膠囊聯(lián)合米非司酮治療子宮肌瘤具有較好的臨床療效，可有效緩解患者癥狀體征，調(diào)控機(jī)體性激素水平，提高免疫功能，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Pingxiao Capsules combined with mifepristone in treatment of uterine fibroids. Methods Patients (134 cases) with uterine fibroids in the Second People's Hospital of Hengshui from June 2015 to June 2017 were randomly divided into control (67 cases) and treatment (67 cases) groups. Patients in the control group were po administered with Mifepristone Tablets since the second day of menstruation, 25 mg/time, once daily. Patients in the treatment group were po administered Pingxiao Capsules on the basis of the control group, 1.38 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the changes of FSH, P, E₂, volume of uterine fibroids, IL-6, percentage of CD³⁺ T cells, CD⁴⁺/CD⁸⁺, expression intensity of PR and EGFR in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.6% and 91.0%, respectively, and there was difference between two groups (P < 0.05). After treatment, FSH, P, E₂, volume of uterine fibroids, IL-6, expression intensity of PR and EGFR in two groups were decreased, but percentage of CD³⁺ T cells, CD⁴⁺/CD⁸⁺ were increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, FSH, P, E₂, volume of uterine fibroids, IL-6, expression intensity of PR and EGFR in the treatment group were lower than those in the control group, but CD³⁺ T cells, CD⁴⁺/CD⁸⁺ were higher than those in the treatment group, and there was difference between two groups (P < 0.05). Conclusion Pingxiao Capsules combined with mifepristone has clinical curative effect in treatment of uterine fibroids, and can relieve symptoms and signs of patients effectively, also can regulate the level of sex hormones and improve immune function, which has a certain clinical application value.